Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD40

CD40

Brief Information

Name:Tumor necrosis factor receptor superfamily member 5
Target Synonym:Bp50,CD40 Antigens,CD40,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CDW40,CD40L Receptor,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,CD40 Molecule, TNF Receptor Superfamily Member 5,TNFRSF5,Tumor Necrosis Factor Receptor Superfamily Member 5,P50,CD40 Antigen,B Cell-Associated Molecule
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:40
Lastest Research Phase:Phase 2 Clinical

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
CD40 mAb Monospecific antibody Oncology/Cancer Advanced solid tumor Phase I Global

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD0-HA256 Human Alexa Fluor™ 647-Labeled Human CD40 Protein, Fc Tag (Site-specific conjugation)
CD0-HA256-structure
CHEK-ATF097 Human Human CD40 (Luc) HEK293 Reporter Cell
CD0-R52H8 Rat Rat CD40 / TNFRSF5 Protein, His Tag (MALS verified)
CD0-R52H8-structure
CD0-R52H8-sds
CD0-M82F3 Mouse Biotinylated Mouse CD40 / TNFRSF5 Protein, Fc,Avitag™ (MALS verified)
CD0-M82F3-structure
CD0-M82F3-sds
CD0-R52H9 Rabbit Rabbit CD40 / TNFRSF5 Protein, His Tag (MALS verified)
CD0-R52H9-structure
CD0-R52H9-sds
CD0-H525a Human Human CD40 / TNFRSF5 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
CD0-H525a-structure
CD0-H525a-sds
TN5-H82F9 Human Biotinylated Human CD40 / TNFRSF5 Protein, Fc,Avitag™ (MALS verified)
TN5-H82F9-structure
TN5-H82F9-sds
CD0-H82E8 Human Biotinylated Human CD40 / TNFRSF5 Protein, Avitag™,His Tag (MALS verified)
CD0-H82E8-structure
CD0-H82E8-sds
CD0-C52H6 Cynomolgus Cynomolgus CD40 / TNFRSF5 Protein, His Tag
CD0-C52H6-structure
CD0-C52H6-sds
TN5-M52H8 Mouse Mouse CD40 / TNFRSF5 Protein, His Tag
TN5-M52H8-structure
TN5-M52H8-sds
TN5-M5259 Mouse Mouse CD40 / TNFRSF5 Protein, Fc Tag
TN5-M5259-structure
TN5-M5259-sds
CD0-C5259 Rhesus macaque Rhesus macaque CD40 / TNFRSF5 Protein, Fc Tag
CD0-C5259-structure
CD0-C5259-sds
CD0-C52H7 Rhesus macaque Rhesus macaque CD40 / TNFRSF5 Protein, His Tag
CD0-C52H7-structure
CD0-C52H7-sds
CD0-H5228 Human Human CD40 / TNFRSF5 Protein, His Tag (MALS verified)
CD0-H5228-structure
CD0-H5228-sds
CD0-H5253 Human Human CD40 / TNFRSF5 Protein, Fc Tag (MALS verified)
CD0-H5253-structure
CD0-H5253-sds
ACRO Quality

Part of Bioactivity data

CD0-HA256-Cell-based assay
 CD40 FACS

5e5 of 293T-CD40L cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of Alexa Fluor 647-Labeled Human CD40 Protein, Fc Tag (Cat. No. CD0-HA256) and negative control protein respectively. Alexa 647 signal was used to evaluate the binding activity (QC tested).

CHEK-ATF097-Cell-based assay
 CD40 FACS

Expression analysis of human CD40 on Human CD40 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human CD40 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human CD40 antibody.

CD0-H525a-BLI
 CD40 BLI

Loaded Human CD40 Protein, Mouse IgG2a Fc Tag (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD0-C5259-BLI
 CD40 BLI

Loaded Rhesus macaque CD40, Fc Tag (Cat. No. CD0-C5259) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.829 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50

Background

CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and  p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD40.HIVRI.Env Vaccine Phase 1 Clinical Anrs, LinKinVax HIV Infections Details
HPV CD40 HVac Phase 2 Clinical LinKinVax Head and Neck Neoplasms; Oropharyngeal Neoplasms Details
SHR-1704 SHR-1704 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Neoplasms Details
Dalnicastobart LVGN7409; LVGN-7409 Phase 2 Clinical Lyvgen Biopharma(HK)Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
BI-655064 BI-655064 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis Details
Sotigalimab APX-005M; EPI-0050; APX-005 Phase 2 Clinical Epitomics Inc Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Skin Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Microsatellite Instability; Sarcoma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
OPT-101 Phase 1 Clinical Op-T LLC Diabetes Mellitus, Type 1 Details
ILB-2101 ILB-2101 Phase 1 Clinical Innolake Biopharm (Hangzhou) Co Ltd Neoplasms Details
Selicrelumab RG-7876; RO-7009789 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
IMB-071703 IMB071703; IMB-071703 Phase 1 Clinical Beijng Immunoah Pharma Tech Co Ltd Solid tumours Details
2141-V11 2141-V11 Phase 2 Clinical The Rockefeller University Solid tumours; Ganglioglioma; Neoplasms; Skin Neoplasms; Glioblastoma; Urinary Bladder Neoplasms; Glioma Details
ABBV-428 ABBV-428; ABBV428 Phase 1 Clinical Abbvie Inc Solid tumours Details
MIL-97 MIL-97 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours Details
NWY-001(Biocytogen Pharmaceuticals) NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasms Details
BSI-038 BSI-038 Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd Solid tumours Details
Bleselumab 4D-11; ASKP-1240 Phase 2 Clinical Kyowa Hakko Kogyo Co Ltd Rejection of renal transplantation; Rejection of organ transplantation; Psoriasis; Glomerulosclerosis, Focal Segmental Details
MP-0317 MP-0317 Phase 1 Clinical Molecular Partners Ag Solid tumours; Neoplasms Details
Inezetamab AMG-994 Phase 1 Clinical Amgen Inc Solid tumours Details
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) Phase 1 Clinical Baylor College Of Medicine Leukemia, Lymphocytic, Chronic, B-Cell Details
Cifurtilimab SEA-CD40 Phase 2 Clinical Seattle Genetics Inc Head and Neck Neoplasms; Lymphoma, B-Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
YH-003 YH-003; YH003 Phase 2 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma Details
Ravagalimab ABBV-323; PR-1629977 Phase 2 Clinical Abbvie Inc Sjogren's Syndrome; Colitis, Ulcerative Details
Giloralimab ABBV-927 Phase 2 Clinical Abbvie Inc Solid tumours; Head and Neck Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SL-172154 SL-172154 Phase 1 Clinical Shattuck Labs Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute Details
NG-350A NG-350A Phase 1 Clinical Akamis Bio Ltd Neoplasms, Glandular and Epithelial; Neoplasm Metastasis Details
BMS-986325 Y 12XX-hz28-P238K Phase 1 Clinical Bristol-Myers Squibb Company Sjogren's Syndrome Details
Iscalimab CFZ-533; NVP-CFZ533; OM11-62-MF Phase 2 Clinical Novartis Pharma Ag Rejection of renal transplantation; Myasthenia Gravis; Diabetes Mellitus, Type 1; Rejection of liver transplantation; Sjogren's Syndrome; Arthritis, Rheumatoid; Lupus Nephritis; Graves Disease; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa Details
Anti-CD40 ChiLob7/4 (BioNTech) Phase 2 Clinical Biontech Se Head and Neck Neoplasms; Pancreatic Neoplasms Details
CD40L-GVAX GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF Phase 2 Clinical University Of South Florida Leukemia; Myelodysplastic Syndromes; Adenocarcinoma of Lung; Lung Neoplasms; Adenocarcinoma; Melanoma Details
KPL-404 KPL-404 Phase 2 Clinical Kiniksa Pharmaceuticals Ltd Arthritis, Rheumatoid Details
NJA-730 NJA-730; NJA-730a; NJA-730b Phase 1 Clinical Napajen Pharma Autoimmune Diseases Details
Mitazalimab ADC-1013; JNJ-7107; JNJ-64457107 Phase 2 Clinical Alligator Bioscience Ab Solid tumours; Neoplasms; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal Details
LNF-1901 LNF-1901; LNF1901 Phase 1 Clinical Lunan Pharmaceutical Group Co Neoplasms Details
Tecaginlimab BNT-312; GEN-1042 Phase 2 Clinical Genmab A/S Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
MEDI-5083 MEDI-5083 Phase 1 Clinical Astrazeneca Plc, Medimmune Solid tumours Details
TQB-2916 TQB2916; TQB-2916 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
DFI-105 DFI105; DFI-105 Phase 2 Clinical Diabetes Free Inc Diabetes Mellitus, Type 2 Details
B-901 B-901; B901 Phase 1 Clinical FutureGen Biopharm (Beijing) Co Ltd Solid tumours Details
RO-7300490 RO-7300490; RG-6189 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms Details
CDX-1140 CDX-1140 Phase 2 Clinical Celldex Therapeutics Bile Duct Neoplasms; Osteosarcoma; Sarcoma; Breast Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Uveal melanoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Esophageal Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Biliary Tract Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Pancreatic Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message